WO2013013351A1 - 复方甲氧那明的速释-缓释渗透泵制剂 - Google Patents

复方甲氧那明的速释-缓释渗透泵制剂 Download PDF

Info

Publication number
WO2013013351A1
WO2013013351A1 PCT/CN2011/001461 CN2011001461W WO2013013351A1 WO 2013013351 A1 WO2013013351 A1 WO 2013013351A1 CN 2011001461 W CN2011001461 W CN 2011001461W WO 2013013351 A1 WO2013013351 A1 WO 2013013351A1
Authority
WO
WIPO (PCT)
Prior art keywords
cellulose
layer
osmotic pump
tablet
drug
Prior art date
Application number
PCT/CN2011/001461
Other languages
English (en)
French (fr)
Inventor
王诺
田武
郑礼亮
Original Assignee
赛乐医药科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赛乐医药科技(上海)有限公司 filed Critical 赛乐医药科技(上海)有限公司
Publication of WO2013013351A1 publication Critical patent/WO2013013351A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents

Definitions

  • the invention relates to a kind of medicine containing phenoxyphene or its hydrochloride, narcotine, aminophylline, chlorpheniramine maleate, 1-70% as immediate release preparation, 99-30% slow An osmotic pump tablet for the release formulation. It is characterized in that the preparation comprises two release parts, one part is an immediate release part, wrapped on the surface of the osmotic pump tablet, so that the medicine can be released quickly when entering the ram, and the other part is a sustained release part, which is contained in the osmotic pump tablet. , Control the sustained release of the drug for up to 8 hours to 24 hours. Background technique
  • Compound oxime is an antiasthmatic drug for bronchial asthma and asthmatic bronchitis.
  • Methoxyphene hydrochloride inhibits bronchospasm and relieves coughing during asthma attacks.
  • Nacod is a peripheral cough suppressant that inhibits coughing.
  • Aminophylline can also inhibit bronchospasm, inhibit swelling of the bronchial mucosa, relieve cough during asthma attacks, and make cough easily.
  • Chlorpheniramine maleate has antihistaminic effects. The compatibility of this product can not only reduce the cough caused by inflammation of the throat and bronchial tubes, but also relieve the cough during the onset of asthma, which is conducive to drainage.
  • the compound methoxyphenamine product is taken by oral administration of 2 capsules once a day, 3 times a day.
  • Chinese Patent No. 200410065967. 4 discloses a preparation method of an oral solid preparation containing methoxyphenamine, narcotine, aminophylline, and chlorpheniramine maleate, and the compound oxime product obtained by the method does not have the product.
  • the effect of sustained release According to the existing method of taking medicines for commercial use, not only the dosage is large, but also the number of times taken is large, which is not conducive to ensuring that patients take medicine on time.
  • Long-acting sustained-release preparations can make up for the shortcomings of immediate release preparations.
  • simple long-acting sustained-release preparations can maintain long-term efficacy, but have slow onset, peak plasma concentration, and release rate are susceptible to gastrointestinal environmental factors (such as pH, gastrointestinal motility).
  • the asthmatic cough medicine has a rapid onset of action to alleviate the symptoms of the patient and can stably maintain long-term efficacy.
  • the osmotic pump long-acting sustained-release preparation can release the drug at a zero-speed, significantly prolonged the release rate of the drug relative to the common preparation (usually 12 to 24 hours), the release rate is not affected by gastrointestinal motility, pH, gastric emptying
  • the advantages of factors such as time.
  • the present invention provides an immediate release preparation with an effective ingredient of 1-70%, and 99-30% is slow.
  • An object of the present invention is to provide an immediate release-sustained release osmotic pump solid preparation having an active ingredient of phenoxygenamine or its hydrochloride, narcotine, aminophylline, and chlorpheniramine maleate.
  • the object of the present invention can be achieved by the following measures:
  • the active ingredient is phenoxygenamine or its hydrochloride, narcotine, aminophylline, chlorpheniramine maleate.
  • the immediate release effect of the present invention is derived from the immediate release portion, which is composed of the active ingredient itself or a mixture with other optional excipients; the sustained release efficacy of the present invention is derived from the sustained release portion of the immediate release-sustained release preparation.
  • the sustained release portion is an osmotic pump sheet comprising a drug-containing layer and a boost layer.
  • the sustained release portion that is, the osmotic pump sheet, contains active ingredients, functional excipients, and optional excipients.
  • the active ingredient is nail oxynamin or its hydrochloride, narcotine, aminophylline and chlorpheniramine maleate.
  • the functional excipients include semipermeable membrane materials, boosters, suspensions and osmotic active agents. One or more of them; with or without other excipients, other excipients include: fillers, binders, plasticizers, colorants, lubricants.
  • the semipermeable membrane material refers to: cellulose esters, cellulose ethers and cellulose ester-ethers such as cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose propionate, cellulose acetate propionate , cellulose acetate butyrate, cellulose trivalerate, cellulose triacetate, cellulose triterpenoid, cellulose trioctanoate, cellulose tripropionate, cellulose disuccinate, dipalmitate Ester cellulose, cellulose dioctanoyl ester, cellulose dicaprylate, cellulose acetate valerate, cellulose acetate succinate, cellulose succinate propionate, cellulose acetate octanoate, cellulose valerate palmitate, Acetic acid heptanoic acid cellulose, acetal acetal cellulose; polyamino phthalate ethyl acetate cellulose acetate; polyamino phthalic acid methyl acetate cellulose acetate
  • the preparation method of the compound instant release-sustained release osmotic pump tablet preparation according to the present invention is as follows:
  • the tablet is an osmotic pump sheet consisting of a sustained release core, a semipermeable membrane coating layer, an immediate release layer, and an optional conventional film coating layer;
  • the sustained release tablet core is an osmotic pump tablet containing the active ingredients ( ⁇ oxyxamine hydrochloride, narcotine, aminophylline, chlorpheniramine maleate); containing booster, suspension, osmotic activity
  • the other excipients include: a filler, a binder, a lubricant and a colorant; the sustained release core material is compressed into a tablet;
  • the osmotic pump sheet prepared above is coated with a common film coating.
  • the tablet is an osmotic pump sheet consisting of a core, a semipermeable membrane coating layer, an immediate release layer, and an optional conventional film coating layer;
  • the core comprises a booster layer and a drug-containing layer;
  • the drug-containing layer contains active ingredients ( ⁇ oxyxamine hydrochloride, narcotine, aminophylline, chlorpheniramine maleate); Containing one or more of a boosting agent, a suspending agent, and an osmotic active agent; and the core has or does not contain other excipients, and other excipients include: fillers, binders, lubricants, and colorants;
  • the drug layer and the booster laminate are made into a double layer sheet;
  • One or more release orifices are laser or mechanically applied to the semipermeable membrane on the drug-containing side;
  • the osmotic pump sheet prepared above is coated with a common film coating.
  • the tablet is an osmotic pump sheet consisting of a core, a semipermeable membrane coating layer, an immediate release layer, and an optional conventional film coating layer;
  • the core contains a layer of booster layer and two layers of drug-containing layer; the drug-containing layer contains active ingredients (oxyxazone hydrochloride, narcotine, aminophylline, chlorpheniramine maleate); booster layer Contains one or more of a booster, a suspension, and an osmotic active agent; with or without other excipients, other excipients include: fillers, binders, lubricants, and colorants;
  • the drug layer and a layer of booster laminate are made into a three-layer tablet with a boost layer and a drug-containing layer in the middle.
  • One or more release holes are respectively laser or mechanically applied to the semipermeable membrane on both sides of the drug;
  • the osmotic pump sheet prepared above is coated with a common film coating.
  • Figure 1 is a graph showing the dissolution profile of the immediate release-sustained release osmotic pump tablet obtained in Example 1;
  • Fig. 2 is a graph showing the dissolution profile of the immediate release-sustained release osmotic pump tablet obtained in Example 2. detailed description
  • Core - drug-containing layer
  • Core - boost layer Polyoxyethylene WSR301 26. 3 140
  • the core-containing drug-containing layer mixture is prepared by dry mixing, or dry granulation, or wet granulation according to the ratio of the above formula amount.
  • Dry-mixing process preparation method adding the active ingredients ( ⁇ oxynamin hydrochloride, narcotine, aminophylline, chlorpheniramine maleate) to polyoxyethylene N80, stirring and hooking; adding magnesium stearate, stirring into The average sentence is made into a core-containing drug layer mixture.
  • active ingredients ⁇ oxynamin hydrochloride, narcotine, aminophylline, chlorpheniramine maleate
  • Preparation method of dry granulation process adding active ingredients ( ⁇ oxynamin hydrochloride, narcotine, aminophylline, chlorpheniramine maleate) to polyoxyethylene N80, stirring to make a mixture of the above, the above mixture Extruded into a sheet or a block; the sheet or block is pulverized so that it can pass through the Chinese Pharmacopoeia No. 2 sieve; the sieved granules are added with magnesium stearate and stirred uniformly; The core contains a mixture of drug layers.
  • active ingredients ⁇ oxynamin hydrochloride, narcotine, aminophylline, chlorpheniramine maleate
  • Preparation method of wet granulation process Add the active ingredients ( ⁇ oxynamin hydrochloride, narcotine, aminophylline, chlorpheniramine maleate) to polyoxyethylene N80, stir to make a homogeneous mixture, and add appropriate amount to the mixture.
  • the ethanol solution is stirred and granulated and dried; then the dried granules are divided into 4 parts so that they can all pass through the Chinese Pharmacopoeia No. 2 sieve; the sieved granules are added with magnesium stearate and stirred uniformly; Core core containing drug layer mixture.
  • the core booster layer mixture is prepared by dry blending, or dry granulation, or wet granulation according to the ratio of the above formula amounts.
  • Dry-mixing process preparation method Mixing polyoxyethylene WSR301, sodium chloride and iron oxide, and stirring uniformly; adding magnesium stearate and stirring to form a core-assisted layer mixture.
  • Dry granulation process preparation method Mixing polyoxyethylene hydrazine WSR30 sodium chloride and iron oxide, stirring Mixing the mixture into a flake or a cake; pulverizing the flakes or chunks to pass all the Chinese Pharmacopoeia No. 2 sieve; adding the stearic acid to the sieved granules Magnesium, stir well; make a core booster layer mixture.
  • Preparation method of wet granulation process Mixing polyoxyethylene WSR301, sodium chloride and iron oxide to make a mixture; adding appropriate amount of water or ethanol solution to the mixture, stirring to make granules and drying; The dried granules are pulverized so that they can all pass through the Chinese Pharmacopoeia No. 2 sieve; the sieved granules are added with stearic acid and stirred uniformly; and the core-assisted layer mixture is prepared.
  • the core-containing drug layer mixture is divided into two parts, and the core-assisted layer mixture is pressed into a three-layer tablet by using a specific three-layer tablet press, wherein the drug-containing layer is on two layers, and the middle is a boost layer;
  • a hidden release hole having a diameter of 0.8 in a laser or mechanical manner on a semipermeable membrane film having a drug layer on both sides;
  • the active ingredient of the immediate release portion and hydroxypropylmethylcellulose are dissolved in water or an ethanol solvent to prepare a coating solution containing the active ingredient, and the solution is coated on the surface of the above-mentioned perforated osmotic pump sheet.
  • Core - drug-containing layer
  • Chlorpheniramine maleate 1. 3 10. 2 Polyoxyethylene N80 25. 4 200
  • Methoxyphenamine hydrochloride 1. 4 11. 25 That can be 0. 8 6. 3
  • the core-containing drug-containing layer mixture is prepared by dry mixing, or dry granulation, or wet granulation according to the ratio of the above formula amount.
  • Dry-mixing process preparation method adding the active ingredients (nioxetamine hydrochloride, narcotine, aminophylline, chlorpheniramine maleate) to polyoxyethylene N80, stirring and hooking; adding magnesium stearate, stirring into They are all made into a core-containing drug layer mixture.
  • active ingredients nioxetamine hydrochloride, narcotine, aminophylline, chlorpheniramine maleate
  • Preparation method of dry granulation process adding active ingredients ( ⁇ oxynamin hydrochloride, narcotine, amino tea ⁇ , chlorpheniramine maleate) to polyoxyethylene N80, stirring to make a mixture of hooks, and squeezing the mixture Pressed into a sheet or a block; the sheet or block 4 is further divided so that it can pass through the Chinese Pharmacopoeia No. 2 sieve; the sieved granules are added with magnesium stearate, and the mixture is stirred;
  • the core tablet contains a drug layer mixture.
  • Preparation method of wet granulation process adding active ingredients (methoxamine hydrochloride, narcotine, aminophylline, chlorpheniramine maleate) to polyoxyethylene N80, stirring to make a homogeneous mixture, adding in the mixture Appropriate amount of ethanol solution, stir to make granules and dry; then pulverize the dried granules so that they can all pass the Chinese Pharmacopoeia No. 2 sieve; the sieved granules are added with magnesium stearate and stirred evenly; The core contains a mixture of drug layers.
  • active ingredients methoxamine hydrochloride, narcotine, aminophylline, chlorpheniramine maleate
  • the core booster layer mixture is prepared by dry blending, or dry granulation, or wet granulation according to the ratio of the above formula amounts.
  • Dry-mixing process preparation method Mixing polyoxyethylene WSR301, sodium chloride and iron oxide, and stirring uniformly; adding magnesium stearate and stirring to form a core-assisted layer mixture.
  • Dry granulation process preparation method mixing polyoxyethylene WSR301, sodium chloride, iron oxide, stirring to make a mixture of hooks, extruding the mixture into a sheet or a block; and then forming the sheet or block
  • the material is pulverized so that it can pass through the Chinese Pharmacopoeia No. 2 sieve; the sieved granules are added with magnesium stearate and stirred uniformly; and the core-assisted layer mixture is prepared.
  • Preparation method of wet granulation process Mixing polyoxyethylene WSR301, sodium chloride and iron oxide to make a mixture; adding appropriate amount of water or ethanol solution to the mixture, stirring to make granules and drying; The dried granules are pulverized so that they can all pass through the Chinese Pharmacopoeia No. 2 sieve; the sieved granules are added with magnesium stearate and stirred uniformly; and the core-assisted layer mixture is prepared.
  • the core drug-containing layer mixture and the core-assisted layer mixture are pressed into a double-layer tablet by using a specific double-layer tablet machine;
  • a hidden release hole having a diameter of 0.8 is laser or mechanically applied to the semipermeable membrane film on the side of the drug-containing layer;
  • the active ingredient of the immediate release portion and the hydroxypropenylcellulose are dissolved in water or an ethanol solvent to prepare a coating solution containing the active ingredient, and the solution is coated on the surface of the above-mentioned perforated osmotic pump sheet.
  • the Opadry I I is dissolved in water to prepare a film coating solution, and the above osmotic pump sheet is coated with the solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)

Abstract

一种含有甲氧那明或其盐酸盐、那可丁、氨茶碱、马来酸氯苯那敏的速释-缓释渗透泵片剂。该制剂包含两个释药部分,一部分为速释部分,含有1-70%的有效成分,包裹于渗透泵片剂表面,使得药物在进入胃部可快速释放;另一部分为缓释部分,含有30-99%的有效成分,包含于渗透泵片剂内部,控制药物持续释放可达8小时至24小时。

Description

复方曱氧那明的速释-緩释渗透泵制剂 技术领域
本发明涉及一类含有药物成分为曱氧那明或其盐酸盐、 那可丁、 氨茶碱、 马来 酸氯苯那敏, 1-70%为速释制剂, 99- 30%为緩释制剂的渗透泵片剂。 其特征在于该 制剂包含两个释药部分, 一部分为速释部分, 包裹于渗透泵片剂表面, 使得药物在 进入冒部可快速释放; 另一部分为缓释部分, 包含于渗透泵片剂内部, 控制药物的 持续释放可达 8小时至 24小时。 背景技术
复方曱氧那明为平喘药,用于支气管哮喘和喘息性支气管炎。盐酸甲氧那明可 抑制支气管痉挛, 緩解哮喘发作时的咳嗽。 那可丁为外周性止咳药, 可抑制咳嗽。 氨茶碱亦可抑制支气管痉挛, 还可抑制支气管粘膜肿胀, 緩解哮喘发作时的咳嗽, 使痰易咳出。马来酸氯苯那敏具抗组胺作用。本品的配伍不仅可以减轻咽喉及支气 管炎症等引起的咳嗽, 而且可緩解哮喘发作时的咳嗽, 有利于排痰。 目前复方甲氧 那明产品的服用方法为口服一次 2粒, 一日 3次。
中国专利 200410065967. 4公布了含有甲氧那明、 那可丁、 氨茶碱、 马来酸氯 苯那敏的口服固体制剂的制备方法,使用该方法制得的复方曱氧那明产品不具备缓 释释放的功效。按照现有的市售药品服用方法, 不仅服用剂量较大, 而且服用次数 多, 不利于保障病患者按时吃药。 长效缓释制剂可以弥补速释制剂的缺陷。 但是 单纯的普通长效緩释制剂虽能维持长时间的药效,但有起效慢、血药浓度峰谷现象、 释药速率易受胃肠道环境因素(如 PH 值、 胃肠道蠕动等)影响的缺点。 而平喘止咳 药有迅速起效緩解病患症状、并能稳定维持长时间的药效的需求。渗透泵长效緩释 制剂能够使药物以零级速度释放、 相对于普通制剂药物恒速释放时间明显延长(通 常为 12 ~ 24小时) 、 释药速度不受胃肠蠕动、 pH、 胃排空时间等因素影响的优点。 基于现有制剂产品的缺点以及平喘止咳药既要起效快, 又要维持长效的需求, 本发 明提供了一种将有效成分 1-70%为速释制剂, 99-30%为緩释制剂, 缓释释放达 8至 24 小时的复方曱氧那明的速释 -緩释渗透泵制剂。 本发明可实现药物迅速发挥药 效, 且能维持药效达 8至 24小时。 发明内容 本发明的目的是提供一种有效成分为曱氧那明或其盐酸盐、 那可丁、 氨茶碱、 马来酸氯苯那敏的速释 -緩释渗透泵固体制剂。
本发明的目的可以通过以下措施来达到:
有效成分为曱氧那明或其盐酸盐、 那可丁、 氨茶碱、 马来酸氯苯那敏。 本发明 的速释功效来源于速释部分,其组成为有效成分本身, 或是与其它可选的辅料制成 的混合物; 本发明的緩释功效来源于速释-緩释制剂的緩释部分, 其特征为緩释部 分为渗透泵片, 包含含药层和助推层。
其緩释部分即渗透泵片包含有效成分、功能性辅料及可选辅料。有效成分是指 甲氧那明或其盐酸盐、 那可丁、氨茶碱和马来酸氯苯那敏, 功能性辅料包含半透膜 材料、助推剂、混悬剂和渗透压活性剂中的一种或几种;并包含或不包含其它辅料, 其他辅料包括: 填充剂、 粘合剂、 增塑剂、 着色剂、 润滑剂。 所述的半透膜材料是 指: 纤维素酯类, 纤维素醚类 和纤维素酯-醚类如醋酸纤维素、 二醋酸纤维素、 三 醋酸纤维素、 丙酸纤维素、 醋酸丙酸纤维素、 醋酸丁酸纤维素、 三戊酸纤维素、 对 三醋酸纤维素、 三椋榈酸酯纤维素、 纤维素三辛酰酯、 三丙酸纤维素、 二琥珀酸纤 维素、二棕榈酸酯纤维素、纤维素二辛酰酯、纤维素二辛酸酯、醋酸戊酸纤维素, 琥 珀酸醋酸纤维素、 琥珀酸丙酸纤维素、 醋酸辛酸纤维素、 戊酸棕榈酸酯纤维素、 醋 酸庚酸纤维素、 乙二曱缩醛纤维素; 聚氨基曱酸乙酯醋酸纤维素; 聚氨基曱酸甲酯 醋酸纤维素; 二曱氨酸乙酸酯纤维素; 聚酰胺半透膜; 聚氨酯半透膜; 磺化聚苯乙 烯半透膜; 乙基纤维素等其中的一种或几种; 混悬剂是指: 羟丙基纤维素、 羟乙基 纤维素、 羟丙基曱基纤维素、 聚乙烯吡咯垸酮、 聚乙二醇、 羟丙乙基纤维素、 羟丙 丁基纤维素、 羟丙戊基纤维素、 海藻酸钠、 羟丙基甲基纤维素、 聚乙烯、 聚环氧乙 烷、 聚氧乙烯、 阿拉伯胶、 羧曱基淀粉钠、 低取代羟丙基纤维素、 交联羧甲基纤维 素钠、聚乙烯吡咯烷酮、卡波普等其中的一种或几种; 渗透压活性剂是指: 氯化钠、 氯化钾、 硫酸镁、 硫酸钠、 乳糖、 果糖、 甘露醇、 葡萄糖、 蔗糖、 磷酸氢二钠、 氯 化锂、 氯化镁、 硫酸钾、 硫酸锂、 磷酸钾、 尿素、 肌醇、 琥珀酸镁、 酒石酸、 棉籽 糖, 山梨糖、 无机盐、 有机盐和糖类等其中的一种或几种; 助推剂是指:高分子量 聚环氧乙烷、 交联羧曱基纤维素碱; 聚丙烯酸(如商品名为 Good-r i te®的聚丙烯 酸), 分子量在 80000 至 200000 ; 丙烯酸多糖聚合物 (如聚葡萄糖, 商品名为 Aqua-Keep®, 聚丙烯酸葡萄糖二酯); 聚丙烯酰胺(商品名为 Cyanamer® )、 羧曱 基淀粉钠、 乙醇淀粉钠、 交联羧曱基纤维素钠、 交联吡咯烷酮、 低取代羟丙甲基纤 维素等其中的一种或几种; 填充剂是指: 微晶纤维素、 二氧化硅化微晶纤维素、 乳 糖、 淀粉、 预胶化淀粉、 磷酸氢钙、 碳酸钙、 甘露醇、 果糖、 蔗糖等其中的一种或 几种; 粘合剂是指: 聚乙烯吡咯烷酮、 纤维素类衍生物如羟曱基纤维素钠等、 淀粉 及预胶化淀粉等其中的一种或几种; 增塑剂是指: 聚乙二醇、 邻苯二曱酸曱酯、 邻 苯二甲酸乙酯、 邻苯二曱酸丁酯、 柠檬酸三乙酯、 柠檬酸酯等其中的一种或几种; 着色剂是指: 各种天然及合成色淀、 金属化合物如氧化铁红等其中的一种或几种; 润滑剂是指: 二氧化硅、 滑石粉、 硬脂酸、 硬脂酸镁、 硬脂富马酸钠、 山嵛酸甘油 酯等其中的一种或几种。
本发明所述的复方速释 -緩释渗透泵片制剂的制备方法如下:
片剂制备方法一:
1. 片剂为渗透泵片, 由缓释片芯、 半透膜材料包衣层、 速释药层、 和可选的 普通薄膜包衣层组成;
2. 緩释片芯为渗透泵片, 包含有效成分(盐酸曱氧那明、 那可丁、 氨茶碱、 马来酸氯苯那敏); 含有助推剂、 混悬剂、 渗透压活性剂等辅料中的一种或几种, 并包含或不包含其它辅料, 其它辅料包括: 填充剂、 粘合剂、 润滑剂和着色剂; 将 该緩释片芯物料压制成片剂;
3. 将由 2)制得的片剂以半透膜材料包衣;
4. 在半透膜衣膜上以激光或者机械方法在一面或者双面打一个或多个释药 孔;
5. 将速释部分的有效成分和粘合剂溶于溶剂中, 配制成含有有效成分的溶液, 用该溶液将有效成分包裹于上述打好孔的渗透泵片表面;
6. 可选的, 将上述制备完成的渗透泵片包普通薄膜衣。
片剂制备方法二:
1. 片剂为渗透泵片, 由片芯、 半透膜材料包衣层、 速释药层、 和可选的普通 薄膜包衣层组成;
2. 片芯包含一层助推层和一层含药层; 含药层含有效成分(盐酸曱氧那明、 那可丁、 氨茶碱、 马来酸氯苯那敏); 助推层含有助推剂、 混悬剂、 渗透压活性剂 中的一种或几种; 并且片芯包含或不包含其它辅料, 其它辅料包括: 填充剂、 粘合 剂、 润滑剂和着色剂; 将含药层和助推层压制成双层片;
3. 将由含药层和助推层制成的双层片剂以半透膜材料包衣;
4. 在含药侧的半透膜衣膜上以激光或者机械方法打一个或多个释药孔;
5. 将速释部分的有效成分和粘合剂溶于溶剂中, 配制成含有有效成分的溶液, 用该溶液将有效成分包裹于上述打好孔的渗透泵片表面。
6. 可选的, 将上述制备完成的渗透泵片包普通薄膜衣。
片剂制备方法三:
1. 片剂为渗透泵片, 由片芯、 半透膜材料包衣层、 速释药层、 和可选的普通 薄膜包衣层组成;
2. 片芯包含一层助推层和两层含药层; 含药层含有效成分(盐酸曱氧那明、 那可丁、 氨茶碱、 马来酸氯苯那敏); 助推层含有助推剂、 混悬剂、 渗透压活性剂 中的一种或几种; 并包含或不包含其它辅料, 其它辅料包括: 填充剂、 粘合剂、 润 滑剂和着色剂; 将两层含药层和一层助推层压制成中间为助推层、上下为含药层的 三层片剂
3. 将由含药层和助推层制成的三层片剂以半透膜材料包衣;
4. 在含药两侧的半透膜衣膜上以激光或者机械方法各打一个或多个释药孔;
5. 将速释部分的有效成分和粘合剂溶于溶剂中, 配制成含有有效成分的溶液, 用该溶液将有效成分包裹于上述打好孔的渗透泵片表面。
6. 可选的, 将上述制备完成的渗透泵片包普通薄膜衣。 附图说明
图 1表示实施例 1所得速释-緩释渗透泵片剂的溶出度曲线图;
图 2表示实施例 2所得速释 -緩释渗透泵片剂的溶出度曲线图。 具体实施方式
下面列举一些具体实施例对本发明做进一步详细的说明 ,但不仅仅局限于下述 实施例:
实施例 1 :
原辅料名称 百分比 (% ) 剂量 ( mg/片 )
片芯-含药层:
盐酸曱氧那明 4. 9 26. 25
那可丁 2. 8 14. 7
氨茶碱 9. 8 52. 5
马来酸氯苯那敏 0. 8 4. 2
聚氧乙烯 N80 27. 2 145
硬脂酸镁 0. 4
片芯-助推层: 聚氧乙烯 WSR301 26. 3 140
氯化钠 7. 5 40
氧化铁 0. 1 0. 5
硬脂酸镁 0. 2 1
半透膜包衣层:
醋酸纤维素 7. 1 38
聚乙二醇 0. 4 2
速释包衣层:
盐酸甲氧那明 2. 1 11. 25
那可丁 1. 2 6. 3
氨茶碱 4. 2 22. 5
马来酸氯苯那敏 0. 3 1. 8 羟丙曱基纤维素 1. 9 10 薄膜衣包衣层:
欧巴代 I I 2. 8 15
制备工艺:
按照上述配方量的比例, 用干混, 或干法制粒, 或湿法制粒工艺制成片芯含药 层混合物。
干混工艺制备方法: 将有效成分(盐酸曱氧那明、 那可丁、 氨茶碱、 马来酸氯 苯那敏)加入聚氧乙烯 N80 , 搅拌均勾; 加入硬脂酸镁, 搅拌成均句制成片芯含药 层混合物。
干法制粒工艺制备方法: 将有效成分(盐酸曱氧那明、 那可丁、 氨茶碱、 马来 酸氯苯那敏)加入聚氧乙浠 N80 , 搅拌制成均勾混合物, 将上述混合物挤压成片状 或块状物; 再将所述片状或块状物粉碎, 使之能全部通过中国药典二号筛; 过筛后 的颗粒加入硬脂酸镁, 搅拌均匀; 制成片芯含药层混合物。
湿法制粒工艺制备方法: 将有效成分(盐酸曱氧那明、 那可丁、 氨茶碱、 马来 酸氯苯那敏)加入聚氧乙烯 N80 , 搅拌制成均匀混合物, 在混合物中加入适量的乙 醇溶液, 搅拌制成颗粒并烘干; 再将烘干后的颗粒 4分碎, 使之能全部通过中国药典 二号筛; 过筛后的颗粒加入硬脂酸镁, 搅拌均匀; 制成片芯含药层混合物。
按照上述配方量的比例, 用干混, 或干法制粒, 或湿法制粒工艺制成片芯助推层混 合物。
干混工艺制备方法: 将聚氧乙烯 WSR301、 氯化钠、 氧化铁混合, 搅拌均匀; 加入硬脂酸镁, 搅拌成均匀制成片芯助推层混合物。
干法制粒工艺制备方法: 将聚氧乙浠 WSR30 氯化钠、 氧化铁混合, 搅拌制 成均勾混合物, 将上述混合物挤压成片状或块状物; 再将所述片状或块状物粉碎, 使之能全部通过中国药典二号筛; 过筛后的颗粒加入硬脂酸镁, 搅拌均匀; 制成片 芯助推层混合物。
湿法制粒工艺制备方法: 将聚氧乙烯 WSR301、 氯化钠、 氧化铁混合, 搅拌制 成均勾混合物; 在混合物中加入适量的水或乙醇溶液, 搅拌制成颗粒并烘干; 再将 烘干后的颗粒粉碎,使之能全部通过中国药典二号篩;过筛后的颗粒加入硬脂酸摸, 搅拌均匀; 制成片芯助推层混合物。
将片芯含药层混合物等分成 2 份, 和片芯助推层混合物采用特定的三层片压 片机, 压制成三层药片, 其中含药层在上下两层, 中间为助推层;
将醋酸纤维素和聚乙二醇加入丙酮和乙醇比例为 3: 1的溶剂中,配制成半透膜 包衣溶液。 将上述由含药层和助推层制成的三层片剂以半透膜材料包衣;
在两侧含药层的半透膜衣膜上以激光或者机械方法打一直径为 0. 8隱 的释药 孔;
将速释部分的有效成分和羟丙甲基纤维素溶于水或者乙醇溶剂中,配制成含有 有效成分的包衣溶液, 用该溶液包裹于将上述打好孔的渗透泵片的表面。
将欧巴代 I I溶于水中, 配制成薄膜衣包衣溶液, 用该溶液将上述渗透泵片包衣。 实施例 2:
原辅料名称 百分比 ( % ) 剂量(mg/片 )
片芯-含药层:
盐酸曱氧那明 8. 1 63. 75
那可丁 4. 5 35. 7
氨茶碱 16. 2 127. 5
马来酸氯苯那敏 1. 3 10. 2 聚氧乙烯 N80 25. 4 200
硬脂酸镁 0. 5 4
片芯-助推层:
聚氧乙烯 WSR301 19. 8 156
氯化钠 5. 3 42
氧化铁 0. 1 0. 6
硬脂酸镁 0. 2 1. 2
半透膜包衣层:
醋酸纤维素 8. 9 38
聚乙二醇 0. 5 2
速释包衣层:
盐酸甲氧那明 1. 4 11. 25 那可丁 0. 8 6. 3
氨茶碱 2. 9 22. 5
马来酸氯苯那敏 0. 2 1. 8 羟丙曱基纤维素 1. 9 15
薄膜衣包衣层:
欧巴代 I I
制备工艺:
按照上述配方量的比例, 用干混, 或干法制粒, 或湿法制粒工艺制成片芯含药 层混合物。
干混工艺制备方法: 将有效成分(盐酸曱氧那明、 那可丁、 氨茶碱、 马来酸氯 苯那敏)加入聚氧乙烯 N80, 搅拌均勾; 加入硬脂酸镁, 搅拌成均勾制成片芯含药 层混合物。
干法制粒工艺制备方法: 将有效成分(盐酸曱氧那明、 那可丁、 氨茶緘、 马来 酸氯苯那敏)加入聚氧乙烯 N80, 搅拌制成均勾混合物, 将上述混合物挤压成片状 或块状物; 再将所述片状或块状物 4分碎, 使之能全部通过中国药典二号筛; 过筛后 的颗粒加入硬脂酸镁, 搅拌均勾; 制成片芯含药层混合物。
湿法制粒工艺制备方法: 将有效成分(盐酸甲氧那明、 那可丁、 氨茶碱、 马来 酸氯苯那敏)加入聚氧乙浠 N80, 搅拌制成均匀混合物, 在混合物中加入适量的乙 醇溶液, 搅拌制成颗粒并烘干; 再将烘干后的颗粒粉碎, 使之能全部通过中国药典 二号筛; 过筛后的颗粒加入硬脂酸镁, 搅拌均匀; 制成片芯含药层混合物。
按照上述配方量的比例, 用干混, 或干法制粒, 或湿法制粒工艺制成片芯助推层混 合物。
干混工艺制备方法: 将聚氧乙烯 WSR301、 氯化钠、 氧化铁混合, 搅拌均匀; 加入硬脂酸镁, 搅拌成均勾制成片芯助推层混合物。
干法制粒工艺制备方法: 将聚氧乙烯 WSR301、 氯化钠、 氧化铁混合, 搅拌制 成均勾混合物, 将上述混合物挤压成片状或块状物; 再将所述片状或块状物粉碎, 使之能全部通过中国药典二号筛; 过筛后的颗粒加入硬脂酸镁, 搅拌均匀; 制成片 芯助推层混合物。
湿法制粒工艺制备方法: 将聚氧乙烯 WSR301、 氯化钠、 氧化铁混合, 搅拌制 成均勾混合物; 在混合物中加入适量的水或乙醇溶液, 搅拌制成颗粒并烘干; 再将 烘干后的颗粒粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁, 搅拌均匀; 制成片芯助推层混合物。 将片芯含药层混合物和片芯助推层混合物采用特定的双层压片机,压制成双层 药片;
将醋酸纤维素和聚乙二醇加入丙酮和乙醇比例为 3: 1的溶剂中,配制成半透膜 包衣溶液。 将上述由含药层和助推层制成的双层片剂以半透膜材料包衣;
在含药层一侧的半透膜衣膜上以激光或者机械方法打一直径为 0. 8隱 的释药 孔;
将速释部分的有效成分和羟丙曱基纤维素溶于水或者乙醇溶剂中 ,配制成含有 有效成分的包衣溶液, 用该溶液包裹于将上述打好孔的渗透泵片的表面。 将欧巴代 I I溶于水中, 配制成薄膜衣包衣溶液, 用该溶液将上述渗透泵片包衣。

Claims

权利要求
1. 一种复方曱氧那明的速释-緩释渗透泵片剂, 其有效成分为甲氧那明或其 盐酸盐、 那可丁、氨茶碱、 马来酸氯苯那敏,其特征在于该片剂包含两个释药部分, 一部分为速释部分, 包裹于渗透泵片剂表面, 使得药物在进入胃部可快速释放; 另 一部分为緩释部分, 包含于渗透泵片剂内部, 控制药物的持续释放可达 8 小时至 24小时。
2.根据权利要求 1 所述的速释-缓释渗透泵片剂, 其特征在于速释部分含有 1-70%的有效成分, 緩释部分含有 30- 99%的有效成分。
3. 根据权利要求 1所述的速释-緩释渗透泵片剂, 其速释部分包含有效成分: 甲氧那明或其盐酸盐、 那可丁、 氨茶碱、 马来酸氯苯那敏中的一种或几种; 并包含 或不包含其它辅料, 其它辅料包括: 填充剂和粘合剂中的一种或几种。
4. 根据权利要求 1 所述速释-緩释渗透泵片剂, 其缓释部分包含有效成分和 功能性辅料并包含或不包含其它辅料,其中有效成分是指曱氧那明或其盐酸盐、那 可丁、 氨茶碱和马来酸氯苯那敏, 功能性辅料包含半透膜材料、 助推剂、 混悬剂和 渗透压活性剂中的一种或几种; 可选辅料包括: 填充剂、 粘合剂、 增塑剂、 着色剂 和润滑剂中的一种或几种。
5.根据权利要求 4要求所述的緩释部分, 其特征在于所述的功能性辅料中, 半透膜材料是指: 醋酸纤维素、 二醋酸纤维素、 三醋酸纤维素、 丙酸纤维素、 醋酸 丙酸纤维素、 醋酸丁酸纤维素、 三戊酸纤维素、 对三醋酸纤维素、 三棕榈酸酯纤维 素、 纤维素三辛酰酯、 三丙酸纤维素、 二琥珀酸纤维素、 二棕榈酸酯纤维素、 纤维 素二辛酰酯、 纤维素二辛酸酯、 醋酸戊酸纤维素, 琥珀酸醋酸纤维素、 琥珀酸丙酸 纤维素、 醋酸辛酸纤维素、 戊酸棕榈酸酯纤维素、 醋酸庚酸纤维素、 乙二曱缩醛纤 维素; 聚氨基甲酸乙酯醋酸纤维素; 聚氨基曱酸甲酯醋酸纤维素; 二曱氨酸乙酸酯 纤维素; 聚酰胺半透膜; 聚氨酯半透膜; 磺化聚苯乙烯半透膜; 乙基纤维素中的一 种或几种; 混悬剂是指: 羟丙基纤维素、 羟乙基纤维素、 羟丙基曱基纤维素、 聚乙 烯吡咯烷酮、 聚乙二醇、 羟丙乙基纤维素、 羟丙丁基纤维素、 羟丙戊基纤维素、 海 藻酸钠、 羟丙基甲基纤维素、 聚乙烯、 聚环氧乙烷、 聚氧乙烯、 阿拉伯胶、 羧曱基 淀粉钠、 低取代羟丙基纤维素、 交联羧甲基纤维素钠、 聚乙烯吡咯烷酮、 卡波普中 的一种或几种; 渗透压活性剂是指: 氯化钠、 氯化钾、 硫酸镁、 硫酸钠、 乳糖、 果 糖、 甘露醇、 葡萄糖、 蔗糖、 磷酸氢二钠、 氯化锂、 氯化镁、 硫酸钾、 硫酸裡、 磷 酸钾、 尿素、 肌醇、 琥珀酸镁、 酒石酸、 棉籽糖, 山梨糖中的一种或几种; 助推剂 是指: 高分子量聚环氧乙烷、 交联羧甲基纤维素碱; 聚丙烯酸; 丙烯酸多糖聚合物; 聚丙烯酰胺、 羧甲基淀粉钠、 乙醇淀粉钠、 交联羧甲基纤维素钠、 交联吡咯烷酮、 低取代羟丙曱基纤维素中的一种或几种。
6.根据权利要求 5要求所述的緩释部分, 其特征在于所述的其它辅料中, 填 充剂是指: 微晶纤维素、 二氧化硅化微晶纤维素、 乳糖、 淀粉、 预胶化淀粉、 磷酸 氢钙、 碳酸钙、 甘露醇、 果糖、 蔗糖中的一种或几种; 粘合剂是指: 聚乙烯吡咯烷 酮、纤维素类衍生物、淀粉及预胶化淀粉中的一种或几种; 增塑剂是指: 聚乙二醇、 邻苯二甲酸甲酯、 邻苯二甲酸乙酯、 邻苯二曱酸丁酯、 拧檬酸三乙酯、 柠檬酸酯中 的一种或几种; 着色剂是指: 各种天然及合成色淀、 金属化合物中的一种或几种; 润滑剂是指: 二氧化硅、 滑石粉、 硬脂酸、 硬脂酸镁、 硬脂富马酸钠、 山嵛酸甘油 酯中的一种或几种。
7. 根据权利要求 1-6任一项所述的速释 -緩释渗透泵片剂, 其特征在于:
1) 片剂为渗透泵片, 由緩释片芯、 半透膜材料包衣层、 速释药层、 和可选的 普通薄膜包衣层组成;
2)緩释片芯为渗透泵片, 包含有效成分盐酸曱氧那明、 那可丁、 氨茶减和马 来酸氯苯那敏; 含有助推剂、 混悬剂和渗透压活性剂中的一种或几种, 并包含或不 包含其它辅料, 其它辅料包括: 填充剂、 粘合剂、 润滑剂和着色剂; 将该緩释片芯 物料压制成片剂;
3)将由 2)制得的片剂以半透膜材料包衣;
4)在半透膜衣膜上以激光或者机械方法在一面或者双面打一个或多个释药 孔;
5)将速释部分的有效成分和粘合剂溶于溶剂中, 配制成含有有效成分的溶液, 用该溶液将有效成分包裹于上述打好孔的渗透泵片表面;
6)可选的, 将上述制备完成的渗透泵片包普通薄膜衣。
8. 根据权利要求 1- 6任一项所述的速释-緩释渗透泵片剂, 其特征在于:
1) 片剂为渗透泵片, 由片芯、 半透膜材料包衣层、 速释药层、 和可选的普通 薄膜包衣层组成;
2) 片芯包含一层助推层和一层含药层; 含药层含有效成分盐酸甲氧那明、 那 可丁、氨茶碱和马来酸氯苯那敏; 助推层含有助推剂、 混悬剂和渗透压活性剂中的 一种或几种; 并且片芯包含或不包含其它辅料, 其它辅料包括: 填充剂、 粘合剂、 润滑剂和着色剂; 将含药层和助推层压制成双层片;
3)将由含药层和助推层制成的双层片剂以半透膜材料包衣;
4)在含药侧的半透膜衣膜上以激光或者机械方法打一个或多个释药孔;
5)将速释部分的有效成分和粘合剂溶于溶剂中, 配制成含有有效成分的溶液, 将该溶液以包衣形式包裹于上述打好孔的渗透泵片表面;
6)可选的, 将上述制备完成的渗透泵片包普通薄膜衣。
9.根据权利要求 1-6任一项所述的速释 -緩释渗透泵片剂, 其特征在于:
1) 片剂为渗透泵片, 由片芯、 半透膜材料包衣层、 速释药层、 和可选的普通 薄膜包衣层组成;
2) 片芯包含一层助推层和两层含药层; 含药层含有效成分盐酸曱氧那明、 那 可丁、 氨茶碱和马来酸氯苯那敏; 助推层含有助推剂、 混悬剂和渗透压活性剂中的 一种或几种; 并且片芯包含或不包含其它辅料, 其它辅料包括: 填充剂、 粘合剂、 润滑剂和着色剂;将两层含药层和一层助推层混合物压制成中间为助推层、上下为 含药层的三层片剂;
3)将由含药层和助推层制成的三层片剂以半透膜材料包衣;
4)在含药两侧的半透膜衣膜上以激光或者机械方法各打一个或多个释药孔;
5)将速释部分的有效成分和粘合剂溶于溶剂中, 配制成含有有效成分的溶液, 将该溶液以包衣形式包裹于上述打好孔的渗透泵片表面;
6)可选的, 将上述制备完成的渗透泵片包普通薄膜衣。
PCT/CN2011/001461 2011-07-27 2011-08-30 复方甲氧那明的速释-缓释渗透泵制剂 WO2013013351A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011102111289A CN102319224B (zh) 2011-07-27 2011-07-27 复方甲氧那明的速释-缓释渗透泵制剂
CN201110211128.9 2011-07-27

Publications (1)

Publication Number Publication Date
WO2013013351A1 true WO2013013351A1 (zh) 2013-01-31

Family

ID=45447153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001461 WO2013013351A1 (zh) 2011-07-27 2011-08-30 复方甲氧那明的速释-缓释渗透泵制剂

Country Status (2)

Country Link
CN (1) CN102319224B (zh)
WO (1) WO2013013351A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002141A (zh) * 2014-09-26 2017-08-01 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102319224B (zh) * 2011-07-27 2013-03-20 赛乐医药科技(上海)有限公司 复方甲氧那明的速释-缓释渗透泵制剂
WO2013013509A1 (zh) * 2011-07-27 2013-01-31 赛乐医药科技(上海)有限公司 复方甲氧那明的速释—缓释渗透泵制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1500487A (zh) * 2002-11-18 2004-06-02 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
CN1660107A (zh) * 2004-12-29 2005-08-31 杭州容立医药科技有限公司 复方甲氧那明口服固体制剂及其制备方法
CN101797253A (zh) * 2010-03-18 2010-08-11 四川大学 一种岩白菜素、盐酸西替利嗪复方口服剂型
CN102319224A (zh) * 2011-07-27 2012-01-18 赛乐医药科技(上海)有限公司 复方甲氧那明的速释-缓释渗透泵制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101642444B (zh) * 2008-08-08 2011-09-21 鲁南制药集团股份有限公司 单硝酸异山梨酯双速渗透泵型控释制剂及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1500487A (zh) * 2002-11-18 2004-06-02 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
CN1660107A (zh) * 2004-12-29 2005-08-31 杭州容立医药科技有限公司 复方甲氧那明口服固体制剂及其制备方法
CN101797253A (zh) * 2010-03-18 2010-08-11 四川大学 一种岩白菜素、盐酸西替利嗪复方口服剂型
CN102319224A (zh) * 2011-07-27 2012-01-18 赛乐医药科技(上海)有限公司 复方甲氧那明的速释-缓释渗透泵制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002141A (zh) * 2014-09-26 2017-08-01 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者

Also Published As

Publication number Publication date
CN102319224B (zh) 2013-03-20
CN102319224A (zh) 2012-01-18

Similar Documents

Publication Publication Date Title
CA2604617C (en) Composition containing anti-dementia drug
AU2006271314B2 (en) Gastroretentive formulations and manufacturing process thereof
EP1218889B1 (en) Controlled release compositions comprising nimesulide
JP2009502987A (ja) カルビドパとレボドパを含有する延長放出型固形医薬組成物
KR20020002321A (ko) 미감이 차폐된 약제학적 입자
CN105682648A (zh) 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
CA2392085A1 (en) Carvedilol methanesulfonate
US20060246003A1 (en) Composition containing anti-dementia drug
JP5948648B2 (ja) 安定化されたエペリゾンを含有する徐放性製剤
JP5228359B2 (ja) 主薬粒子及びその製造方法ならびに口腔内崩壊錠
KR20070045247A (ko) 드로스피렌온 및 에티닐에스트라디올을 포함하는 약제학적조성물
JP2008273870A (ja) 経口固形製剤及びその製造方法
KR20110117199A (ko) 유기 화합물의 생약 제제
US20130143897A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2012029838A1 (ja) 口腔内崩壊錠
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
WO2013013351A1 (zh) 复方甲氧那明的速释-缓释渗透泵制剂
US20090117181A1 (en) Tablet comprising fluvastatin and carmellose calcium
AU2016255302B2 (en) Rivastigmine-containing sustained-release pharmaceutical composition
WO2010086868A1 (en) Pharmaceutical compositions of trimetazidine
WO2014003371A1 (ko) 아세브로필린을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
TW202312988A (zh) 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用
WO2013013509A1 (zh) 复方甲氧那明的速释—缓释渗透泵制剂
KR20090107961A (ko) 심혈관계 질환 치료용 약제학적 제제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11869890

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11869890

Country of ref document: EP

Kind code of ref document: A1